Compare RYTM & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | IRTC |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.8B |
| IPO Year | 2017 | 2016 |
| Metric | RYTM | IRTC |
|---|---|---|
| Price | $102.96 | $155.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $129.92 | ★ $217.31 |
| AVG Volume (30 Days) | 616.7K | ★ 642.4K |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $174,334,000.00 | ★ $702,573,000.00 |
| Revenue This Year | $47.78 | $27.42 |
| Revenue Next Year | $56.52 | $17.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.92 | 25.45 |
| 52 Week Low | $45.91 | $92.52 |
| 52 Week High | $122.20 | $212.00 |
| Indicator | RYTM | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 36.05 |
| Support Level | $101.47 | $153.05 |
| Resistance Level | $109.02 | $174.36 |
| Average True Range (ATR) | 5.38 | 8.56 |
| MACD | -0.02 | -1.68 |
| Stochastic Oscillator | 42.64 | 12.08 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.